1. Generics Bulletin
  2. >>Products

Meitheal’s Heparin Launch Builds On Nanjing King-Friend Backing

 
• By Aidan Fry

Launching eight heparin vial presentations in the US is evidence of how injectables specialist Meitheal Pharmaceuticals intends to leverage the vertically-integrated production capacity of its Chinese parent group NKF.

Heparin_Injection
Meitheal is introducing vertically-integrated heparin vials in the US • Source: Shutterstock

US injectables specialist Meitheal Pharmaceuticals has capitalized quickly on its recent takeover by Nanjing King-Friend Biochemical Pharmaceutical by drawing on its Chinese parent company’s vertical integration to launch eight presentations of heparin sodium vials. And by the end of this year, Meitheal intends to add enoxaparin, also supplied by NKF, to its portfolio.

Speaking exclusively to Generics Bulletin just ahead of introducing the eight heparin presentations ranging from 1,000 units per 1ml to...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Generics

More from Products

ViiV Extends Voluntary License For Long-Acting Cabotegravir As HIV Treatment

 
• By Urtė Fultinavičiūtė

The Medicines Patent Pool’s extended voluntary license to produce long-acting cabotegravir to treat HIV is a win for patients living in LMICs, as the WHO updated its guidance to recommend it as an alternative treatment option.

ANDA User Fees: Complex Generics, Transparency, Communications Are Early Negotiation Targets

 
• By Sue Sutter

Teva seeks a dedicated development program and first-cycle approval metrics for complex generics. Role of artificial intelligence in the generic drug review process is a talking point for both agency and industry at reauthorization kickoff meeting.

Kirsty Gives Biocon A First Interchangeable US Insulin Aspart Biosimilar

 
• By Dave Wallace

After years of waiting, Biocon Biologics has finally snagged US FDA approval for its insulin aspart biosimilar – along with a first designation of interchangeability. However, Sanofi’s Merilog version is already approved as a rival to Novo Nordisk’s Novolog.